Source: Health Canada shortage reports · Updated Jul 27, 2026
Some Naproxen products are in shortage in Canada (1 of 8 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.
A nonsteroidal anti-inflammatory drug used to relieve pain and inflammation.
Products affected
1 / 8
In shortage since
Jul 25, 2024
Reports on file
27
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
ANAPROX
275MG · TABLET · ATNAHS PHARMA UK LIMITED
DIN 02162725 · since Jul 25, 2024, no end estimate · Delays by manufacturer.
Resolved
TEVA-NAPROXEN SODIUM DS
550MG · TABLET · TEVA CANADA LIMITED
DIN 02026600 · ended Feb 25, 2026 · Disruption of the manufacture of the drug.
Resolved
TEVA-NAPROXEN SODIUM
275MG · TABLET · TEVA CANADA LIMITED
DIN 00778389 · ended Feb 18, 2026 · Disruption of the manufacture of the drug.
Resolved
TEVA-NAPROXEN SODIUM DS
550MG · TABLET · TEVA CANADA LIMITED
DIN 02026600 · ended Nov 19, 2025 · Disruption of the manufacture of the drug.
Resolved
TEVA-NAPROXEN SODIUM DS
550MG · TABLET · TEVA CANADA LIMITED
DIN 02026600 · ended Aug 19, 2025 · Disruption of the manufacture of the drug.
Discontinued
TEVA-NAPROXEN SODIUM
275MG · TABLET · TEVA CANADA LIMITED
DIN 00778389
Resolved
TEVA-NAPROXEN SODIUM
275MG · TABLET · TEVA CANADA LIMITED
DIN 00778389 · ended Jan 7, 2025 · Disruption of the manufacture of the drug.
Resolved
TEVA-NAPROXEN SODIUM DS
550MG · TABLET · TEVA CANADA LIMITED
DIN 02026600 · ended Nov 8, 2023 · Disruption of the manufacture of the drug.
Resolved
APO-NAPRO-NA DS
550MG · TABLET · APOTEX INC
DIN 01940309 · ended Jul 26, 2023 · Disruption of the manufacture of the drug.
Resolved
ANAPROX
275MG · TABLET · ATNAHS PHARMA UK LIMITED
DIN 02162725 · ended May 25, 2023 · Shortage of an active ingredient.
Resolved
APO-NAPRO-NA DS
550MG · TABLET · APOTEX INC
DIN 01940309 · ended Aug 23, 2022 · Disruption of the manufacture of the drug.
Resolved
APO-NAPRO-NA
275MG · TABLET · APOTEX INC
DIN 00784354 · ended Aug 19, 2022 · Disruption of the manufacture of the drug.
Showing 12 of 27 reports. All reports are on file with Health Canada.
What's happening
Naproxen is currently affected by an active shortage report filed with Health Canada by ATNAHS PHARMA UK LIMITED.
The reported cause is: delays by manufacturer. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Naproxen is classified under “ANTIINFLAMMATORY/ANTIRHEUMATIC PROD.,NON-STEROIDS” (ATC M01AE).
Recent changes
No changes recorded yet.
Common questions
What is Naproxen used for?
A nonsteroidal anti-inflammatory drug used to relieve pain and inflammation.
When will Naproxen be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Naproxen in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.